The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monday Biotech Deal Review: November 9, 2009

B&W_BigNickelSome closings, some new deals, some MDS and some PBM all in this week’s deal review.

Closings

  • Capital Pool Company Calotto Capital Inc. (TSXV: TTO.P) closed its Qualifying Transaction with Hamilton Thorne, Inc., and will start trading as a Tier 2 issuer under the new symbol “HTL” following final Exchange approval.  Hamilton Thorne makes advanced laser systems and instruments for stem cell research.  The concurrent private placement, together with debt conversion, raised $2,200,000 (gross) through the issuance of 18,098.655 units at a price of $121.556 per unit. Each unit is one share of common stock plus one warrant. LOM (still no BioQuest) acted as sole agent and received a cash commission of $135,720 (8% of the aggregate gross proceeds) plus 1,447.892 non-transferable broker warrants (exercisable for 18 months at $121.556) equal to 8.0% of the units sold.
  • Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ: ONCY) saw 100% of eligible warrants exercised and received proceeds of approximately $9.1 million, in advance of the accelerated expiry date. Oncolytics now has about $23.7 million cash on hand, and 56,662,469 shares outstanding.
  • IMRIS Inc. (TSX:IM) closed its bought deal, issuing 3,697,250 common shares for gross proceeds of approximately $20.7 million.

New Offerings

  • GLG Life Tech Corporation (TSX: GLG), following a 4:1 reverse split, is offering 3,625,000 common shares (with a 30-day 15% overalotment) via a Canadian short form prospectus and an initial U.S. public offering (per this MJDS filing). GLG has received conditional approval to list its shares on NASDAQ under symbol “GLGL” following the offering. The lead underwriters are Canaccord Adams and GMP Securities L.P.; and Roth Capital Partners, LLC, Desjardins Securities Inc., and Wellington West Capital Markets Inc. are also in on the deal. 
  • Medicago Inc. (TSXV: MDG) is doing a $10 million bought deal for 14,000,000 subscription receipts.  The syndicate is led by Paradigm Capital Inc. Each receipt represents the right to receive one unit of Medicago (one common share plus one half of a 12-month $1.00 warrant) upon the conversion date, (at the latest December 15, 2009). Proceeds will be used primarily for development of influenza vaccines, and closing is expected on or about November 30, 2009.

MDS Update

MDS Inc. (TSX:MDS) (NYSE:MDZ) And Danaher Corporation (NYSE: DHR) received a second HSR request regarding the sale of MDS Analytical Technologies, which will extend the applicable waiting period. MDS and Danaher estimate the Second Request relates to a global market segment which generates $50 million in annual revenues for all sellers combined.

MDS also closed the sale of its Central Labs operation to private investment group Czura Thornton in Jersey, Channel Islands.

SXC Health Solutions Corp PBM contract

SXC Health Solutions Corp. (NASDAQ: SXCI) (TSX: SXC) announced that its informedRx PBM unit won a four-year contract to provide pharmacy benefit management (PBM) services to Spectral Solutions LLC (which manages an annual drug spend of $50 million), starting on January 1, 2010.

Thanks again to Jacob Cawker for help with this week’s deal review!

Bookmark and Share

About these ads

4 responses to “Monday Biotech Deal Review: November 9, 2009

  1. Pingback: Monday Biotech Deal Review: November 16, 2009 « The Cross-Border Biotech Blog

  2. Pingback: Monday Biotech Deal Review: November 23, 2009 « The Cross-Border Biotech Blog

  3. Pingback: Monday Biotech Deal Review: November 30, 2009 « The Cross-Border Biotech Blog

  4. Pingback: Monday Biotech Deal Review: December 7, 2009 « The Cross-Border Biotech Blog

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 130 other followers